Following is a summary of research performed by investigators at Tel Aviv University and published in the medical journal Clinical Neuropharmacology:
Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study.
Lotan I, Treves TA, Roditi Y, Djaldetti R. Clin Neuropharmacol. 2014 Mar-Apr;37(2):41-4.
In this study, twenty-two patients with Parkinson’s disease were evaluated at baseline and 30 minutes after smoking Cannabis.
After treatment, significant improvement was noted in:
- Bradykinesia (slowness of movement)
- Pain scores
No significant adverse effects of the drug were observed.
Researchers’ Conclusions: The study suggests that cannabis might have a place in the therapeutic armamentarium to treat Parkinson’s disease. Larger, controlled studies are needed to verify the results.
Inhaling whole-plant cannabis provides symptomatic relief in patients with Parkinson’s disease (PD), according to observational trial data published in the March/April edition of the journal Clinical Neuropharmacology. Parkinson’s is a progressive disorder of the central nervous system that results in tremor, slowed movement, and muscle rigidity. Investigators at Tel Aviv University, Department of Neurology evaluated Parkinson’s disease symptoms in 22 patients at baseline and 30-minutes after inhaling cannabis. Researchers reported that inhaled cannabis was associated with “significant improvement after treatment in tremor, rigidity, and bradykinsea (slowness of movement). There was also significant improvement of sleep and pain scores. No significant adverse effects of the drug were observed.” They concluded: “[T]his observational study is the first to report an amelioration of both motor and non–motor symptoms in patients with PD treated with cannabis. The study opens new venues for treatment strategies in PD especially in patients refractory to current medications.” Israel has formally allowed for the licensed production and distribution of the substance for therapeutic purposes since 2011.